Characteristics of superficial esophageal squamous cell carcinomas undetectable with narrow-band imaging endoscopy.
Lugol chromoendoscopy
Lugol-voiding lesions
esophageal squamous cell carcinoma
narrow-band imaging
Journal
Gastroenterology report
ISSN: 2052-0034
Titre abrégé: Gastroenterol Rep (Oxf)
Pays: England
ID NLM: 101620508
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
09
03
2021
revised:
15
06
2021
accepted:
02
07
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
5
11
2021
Statut:
epublish
Résumé
The detection rate of narrow-band imaging (NBI) for superficial esophageal squamous cell carcinoma (SESCC), including high-grade intraepithelial neoplasia, is significantly higher than that of white-light endoscopy. However, there are SESCCs that are undetectable by NBI but detectable by Lugol chromoendoscopy (LCE) and the characteristics of these SESCCs are still unknown. Thus, this study aimed to clarify the characteristics of SESCC that are undetectable using NBI. Patients with current SCC or a history of SCC in the head and neck or in the esophagus were enrolled. The inspection of the esophagus was initiated by NBI, followed by LCE. Biopsies were taken of all suspected SESCC lesions during NBI observation and Lugol-voiding lesions (LVLs) that were irregularly shaped and >5 mm and/or pink in color during LCE observation. The characteristics of SESCC that were undetectable with NBI were statistically analysed. Overall, 147 lesions in 105 cases were histologically diagnosed as SESCC. Twenty in 15 cases were NBI-undetectable lesions, all of which were macroscopic flat type (0-IIb). The median sizes of the NBI-undetectable lesions and NBI-detectable lesions were both 15 mm ( The detection of SESCCs with NBI is challenging when lesions are morphologically completely flat, in cases with numerous irregularly shaped LVLs, and if located at the anterior wall.
Sections du résumé
BACKGROUND
BACKGROUND
The detection rate of narrow-band imaging (NBI) for superficial esophageal squamous cell carcinoma (SESCC), including high-grade intraepithelial neoplasia, is significantly higher than that of white-light endoscopy. However, there are SESCCs that are undetectable by NBI but detectable by Lugol chromoendoscopy (LCE) and the characteristics of these SESCCs are still unknown. Thus, this study aimed to clarify the characteristics of SESCC that are undetectable using NBI.
METHODS
METHODS
Patients with current SCC or a history of SCC in the head and neck or in the esophagus were enrolled. The inspection of the esophagus was initiated by NBI, followed by LCE. Biopsies were taken of all suspected SESCC lesions during NBI observation and Lugol-voiding lesions (LVLs) that were irregularly shaped and >5 mm and/or pink in color during LCE observation. The characteristics of SESCC that were undetectable with NBI were statistically analysed.
RESULTS
RESULTS
Overall, 147 lesions in 105 cases were histologically diagnosed as SESCC. Twenty in 15 cases were NBI-undetectable lesions, all of which were macroscopic flat type (0-IIb). The median sizes of the NBI-undetectable lesions and NBI-detectable lesions were both 15 mm (
CONCLUSIONS
CONCLUSIONS
The detection of SESCCs with NBI is challenging when lesions are morphologically completely flat, in cases with numerous irregularly shaped LVLs, and if located at the anterior wall.
Identifiants
pubmed: 34733525
doi: 10.1093/gastro/goab028
pii: goab028
pmc: PMC8560036
doi:
Types de publication
Journal Article
Langues
eng
Pagination
402-407Informations de copyright
© The Author(s) 2021. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.
Références
J Gastroenterol Hepatol. 2019 Feb;34(2):390-396
pubmed: 30101499
Dig Liver Dis. 2017 Apr;49(4):427-433
pubmed: 28096057
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Gastroenterol Hepatol. 2010 Aug;25(8):1410-5
pubmed: 20659231
J Gastroenterol. 2019 Jun;54(6):501-510
pubmed: 30406847
Endoscopy. 2010 Aug;42(8):613-9
pubmed: 20669074
Gastroenterol Res Pract. 2015;2015:639462
pubmed: 26229530
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2010 Mar 20;28(9):1566-72
pubmed: 20177025
Gastroenterology. 2007 Aug;133(2):454-64; quiz 674
pubmed: 17681166
BMC Cancer. 2017 Jan 13;17(1):54
pubmed: 28086818
Lancet Oncol. 2002 Oct;3(10):604-10
pubmed: 12372722
Gastrointest Endosc. 2009 Aug;70(2):240-5
pubmed: 19386304
Gastrointest Endosc. 2002 Oct;56(4):517-21
pubmed: 12297767
Gastrointest Endosc. 2004 Feb;59(2):288-95
pubmed: 14745410
N Engl J Med. 2003 Dec 4;349(23):2241-52
pubmed: 14657432
Endoscopy. 2008 Sep;40(9):775-8
pubmed: 18698532
Gut. 2000 Aug;47(2):256-61
pubmed: 10896918
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387